DnB Asset Management AS trimmed its position in Xylem Inc (NYSE:XYL) by 17.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,719 shares of the industrial products company’s stock after selling 6,000 shares during the quarter. DnB Asset Management AS’s holdings in Xylem were worth $1,959,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Invictus RG bought a new position in Xylem in the third quarter valued at approximately $104,000. Harfst & Associates Inc. grew its stake in shares of Xylem by 26.1% during the second quarter. Harfst & Associates Inc. now owns 2,433 shares of the industrial products company’s stock worth $134,000 after buying an additional 503 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Xylem during the second quarter worth $168,000. FNY Partners Fund LP grew its stake in shares of Xylem by 2,700.0% during the third quarter. FNY Partners Fund LP now owns 2,800 shares of the industrial products company’s stock worth $175,000 after buying an additional 2,700 shares during the last quarter. Finally, Federated Investors Inc. PA grew its stake in shares of Xylem by 5.8% during the second quarter. Federated Investors Inc. PA now owns 3,286 shares of the industrial products company’s stock worth $182,000 after buying an additional 181 shares during the last quarter. 85.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of Xylem Inc (NYSE XYL) opened at $70.46 on Monday. The company has a quick ratio of 1.26, a current ratio of 1.76 and a debt-to-equity ratio of 0.88. Xylem Inc has a one year low of $46.67 and a one year high of $70.79. The firm has a market cap of $12,654.62, a price-to-earnings ratio of 40.97, a P/E/G ratio of 1.67 and a beta of 1.18.
Xylem (NYSE:XYL) last issued its quarterly earnings data on Tuesday, October 31st. The industrial products company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.01. Xylem had a net margin of 6.85% and a return on equity of 17.74%. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the previous year, the firm posted $0.54 earnings per share. Xylem’s revenue for the quarter was up 33.2% on a year-over-year basis. analysts forecast that Xylem Inc will post 2.39 EPS for the current year.
In related news, Director Curtis J. Crawford sold 7,500 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $66.44, for a total value of $498,300.00. Following the sale, the director now owns 52,385 shares of the company’s stock, valued at $3,480,459.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Tomas Brannemo sold 2,260 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $67.75, for a total transaction of $153,115.00. Following the completion of the sale, the insider now directly owns 10,975 shares in the company, valued at approximately $743,556.25. The disclosure for this sale can be found here. In the last three months, insiders sold 150,777 shares of company stock worth $10,097,757. 0.75% of the stock is currently owned by insiders.
XYL has been the topic of a number of research reports. Cowen reaffirmed a “buy” rating and set a $70.00 target price on shares of Xylem in a research note on Thursday, September 21st. Robert W. Baird reaffirmed a “hold” rating and set a $67.00 target price on shares of Xylem in a research note on Wednesday, October 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $71.00 target price (up previously from $64.00) on shares of Xylem in a research note on Wednesday, October 4th. Zacks Investment Research raised shares of Xylem from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research note on Thursday, October 5th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $56.00 target price on shares of Xylem in a research note on Friday, October 6th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $65.92.
ILLEGAL ACTIVITY WARNING: “Xylem Inc (XYL) Position Cut by DnB Asset Management AS” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/15/xylem-inc-xyl-position-cut-by-dnb-asset-management-as.html.
Xylem Company Profile
Xylem Inc is a water technology company. The Company designs, manufactures and services engineered solutions across a range of critical applications. It is an equipment and service provider for water and wastewater applications with a portfolio of products and services addressing the cycle of water, from collection, distribution and use to the return of water to the environment.
Want to see what other hedge funds are holding XYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xylem Inc (NYSE:XYL).
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.